Prostrakan grants Tostran licence to Bayer Schering
This article was originally published in Scrip
ProStrakanhas granted an exclusive licence to Bayer Schering Pharmato develop and commercialise Tostran (2% testosterone gel) in 65 countries. Bayer Schering will pay ProStrakan an undisclosed amount and milestones upon meeting certain approvals and sales targets. ProStrakan will supply the testosterone replacement therapy for hypogonadal men to Bayer Schering in Canada, Latin America, the Middle East, Africa, and the Asia-Pacific region. ProStrakan currently markets the product in Europe under the brand names Tostran, Tostrex and Itnogen. In the US, where Tostran is to be marketed as Fortigel, the company remained on course to re-submit its NDA for the product to the FDAby the end of the year, ProStrakan said.